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Background: Interleukin (IL)-21 is a member of the type I cytokine family and plays a role in the path-
ogenesis of T helper type 2 allergic diseases. It has been reported that IL-21 expression is upregulated in
acute skin lesions in atopic dermatitis (AD) patients; however, little is known about the serum IL-21
levels of AD patients. The aim of this study was to quantify the serum IL-21 levels of AD patients and
to evaluate the relationships between the serum IL-21 level and disease severity, laboratory markers, and
eruption type in AD patients.
Methods: We measured the serum IL-21 levels of adult AD patients and healthy control subjects using an
enzyme-linked immunosorbent assay.
Results: The adult AD patients exhibited signiﬁcantly higher serum IL-21 levels than the healthy control
subjects. A comparison of the patients' serum IL-21 levels based on the clinical severity of their AD
revealed that the patients with severe AD demonstrated signiﬁcantly higher serum IL-21 levels than
those with mild AD and the healthy control subjects. The serum IL-21 levels were signiﬁcantly correlated
with the skin severity score, and especially with the degree of acute lesions such as erythema and
edema/papules. The serum IL-21 level was not associated with laboratory markers, such as the serum IgE
level, the serum thymus and activation-related chemokine level, blood eosinophilia, and the serum
lactate dehydrogenase level.
Conclusions: These results suggest that IL-21 might be involved in the pathogenesis of AD, especially the
development of acute skin lesions.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Atopic dermatitis (AD) is a common allergic skin disease that is
caused by genetic and environmental background factors.1 It is
characterized by the disturbance of epithelial barrier function and
IgE-mediated sensitization to food and environmental allergens.
Genetic sequencing has identiﬁed several mutations in genes that
encode epidermal structural proteins, such as ﬁlaggrin,2e4 and
cytokines related to IgE synthesis, such as interleukin (IL)-4, IL-5, IL-
12, IL-13, or granulocyte/macrophage-colony stimulating factor.5 T
helper (Th) 2 cytokines, including IL-4, IL-5, and IL-13, predominatey, Graduate School of Medical
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oi.org/10.1016/j.alit.2016.10.0in the acute phase of AD, leading to increased expression of inter-
feron-g, IL-12, and IL-5 in the chronic phase of the condition.1
IL-21 is a member of the type I cytokine family and is produced
by lymphoid cells, such as activated CD4þ T cells, natural killer T
cells, and Th17 cells.6e10 The effects of IL-21 are mediated by the
binding of IL-21 to a heterodimeric receptor, which consists of
common g-chain subunit and a unique receptor (named IL-
21R).6e10 The common g-chain subunit is shared with the IL-2, IL-4,
IL-7, IL-9, and IL-15 receptors. The IL-21R is expressed on immune
cells, such as naïve and activated T cells, B cells, natural killer cells,
dendritic cells, and macrophages, as well as certain types of non-
immune cells, including keratinocytes and endothelial cells.6e10
Several studies have shown that IL-21 contributes to the path-
ogenesis of allergic diseases. Serum IL-21 levels increase during the
acute exacerbation of asthma, and they fall again after treatment.11
In a recent study by Jin et al., it was found that IL-21 and IL-21R
expression were upregulated in the acute skin lesions of AD pa-
tients.12 These ﬁndings suggest that IL-21 signaling plays an
important role in skin inﬂammation in AD. Until now, no detailedvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
s are elevated in atopic dermatitis patients with acute skin lesions,
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relationship between the serum IL-21 level and the severity of AD
have been reported.
Methods
Subjects
A total of 79 adults patients (49 males, 30 females; median age:
36.3 years old; range: 16e62 years old) with AD were randomly
selected and registered for this study. All patients met the diag-
nostic criteria outlined by Haniﬁn and Rajka.13 The severity of their
AD was evaluated using the eczema area and severity index (EASI)
score14 (median score: 22.5; range: 1.5e58.1). Based on the EASI
score, the AD patients were divided into 3 groups: the mild (score:
<10), moderate (score: 10e20), and severe (score: >20) groups.
Skin lesion severity (the scores for erythema, edema/papules,
oozing/crusting, excoriation, licheniﬁcation, and xerosis) and itch-
ing severity were assessed in the worse affected areas of skin, as
described previously.15,16 Peripheral blood samples were obtained
from each patient during the exacerbation of their eruptions. The
peripheral eosinophil count (median: 662/ml; range: 0e3220/ml;
reference range: 50e590/ml), and the serum levels of IgE (median:
12,846 IU/ml; range: 125e80,400 IU/ml; reference range:
0e380 IU/ml), lactate dehydrogenase (LDH) (median: 288 IU/L;
range: 114e762 IU/L; reference range: 140e243 IU/L), and thymus
and activation-related chemokine/chemokine ligand 17 (TARC/
CCL17) (median: 5172 pg/mL; range: 125e46,160 pg/mL; reference
range: 0e449 pg/mL) were measured.
Each patient had been suffering from AD for more than three
years. The patients were treated with conventional therapies,
including topical corticosteroids and calcineurin inhibitors and
systemic antihistamines. Patients that were taking systemic corti-
costeroids or immunosuppressive agents were not included in the
study. The control group consisted of 17 healthy subjects (9males, 8
females; median age: 35.5 years old; range: 28e51 years old) who
had not taken any medication for at least 2 weeks. All of the sub-
jects provided written consent, and the study protocol was
approved by the university ethics committee and was conducted in
accordance with the Declaration of Helsinki.
Measurement of the serum IL-21 level using an enzyme-linked
immunosorbent assay (ELISA)
The subjects' serum IL-21 levels were measured using an ELISA
kit (human IL-21 platinum ELISA eBioscience, San Diego, CA, USA).
The reference range for the ELISA kit was 0e5000 pg/mL. When a
sample's value fell outside of the reference range for this kit, the
samplewas reanalyzed at a higher dilution. All measurements were
conducted in duplicate, and mean values were obtained.
Statistical analysis
Data are expressed as mean ± SD values unless otherwise
indicated. The ManneWhitney U test was used to compare the
serum IL-21 levels of the AD patients with those of the healthy
controls. The Steel test or SteeleDwass test was used for compari-
sons among three or more groups because most of the data were
not normally distributed. Spearman's rank correlation analysis was
used to evaluate the relationships between the serum IL-21 level
and the EASI score; each eruption score; the peripheral eosinophil
count; or the serum levels of IgE, LDH, or TARC. Differences were
considered to be statistically signiﬁcant when the associated
P-value was <0.05.Please cite this article in press as: Mizutani H, et al., Serum IL-21 level
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Serum IL-21 levels of AD patients and healthy controls
The AD patients' serum IL-21 levels (median: 454 pg/mL, n¼ 79)
were signiﬁcantly higher than those of the healthy control subjects
(median: 50.6 pg/mL, n ¼ 17) (P < 0.05) (Fig. 1a).
Correlation between IL-21 and disease severity in patients with AD
To evaluate the relationship between the serum IL-21 level and
skin lesion severity scores, the patients were divided into 3 groups,
the mild, moderate, and severe groups, based on their EASI scores.
When the serum IL-21 levels of these groups were compared, it was
found that the patients with severe AD exhibited signiﬁcantly
higher IL-21 levels than the healthy controls and the patients with
mild AD (P < 0.05) (Fig. 1b). Serum levels of IL-21 were signiﬁcantly
correlated with EASI scores in patients with AD (n ¼ 79, r ¼ 0.24,
P ¼ 0.034; Fig. 2).
Correlation between IL-21 and eruption type in patients with AD
The correlations between the serum IL-21 level and each skin
lesion severity score (erythema, edema/papules, oozing/crusting,
excoriation, licheniﬁcation, and xerosis scores) were evaluated in
the worst affected areas of skin. Among six types of eruptions, er-
ythema, edema/papules, oozing/crusting, excoriation, lichen-
iﬁcation, and xerosis, serum IL-21 levels were signiﬁcantly
correlated with the erythema score (r ¼ 0.24, P ¼ 0.034) and
edema/papules score (r ¼ 0.23, P¼ 0.043), but not with the oozing/
crusting score (r ¼ 0.12, P ¼ 0.33), excoriation score (r ¼ 0.15,
P ¼ 0.20), licheniﬁcation score (r ¼ 0.082, P ¼ 0.48), or xerosis
score (r ¼ 0.075, P ¼ 0.56) (Fig. 3). The itching score was also not
correlated with the serum IL-21 level (r ¼ 0.15, P ¼ 0.24) (Fig. 3).
Correlation between IL-21 and laboratory markers in patients with
AD
Relationship were evaluated between serum levels of IL-21 and
laboratory markers that known to be elevated in patients with AD.
There was no signiﬁcant correlation between IL-21 and serum IgE
(n¼ 72, r¼0.036, P¼ 0.763), peripheral eosinophil count (n¼ 71,
r ¼ 0.030, P ¼ 0.804), serum LDH (n ¼ 73, r ¼ 0.076, P ¼ 0.517), or
TARC (n ¼ 75, r ¼ 0.0080, P ¼ 0.945) (Table 1).
Discussion
The results of our study showed that AD patients displayed
signiﬁcantly higher serum IL-21 levels than healthy controls
(Fig. 1a). In a comparison based on disease severity, it was found
that only patients with severe AD (EASI > 20) had signiﬁcantly
elevated serum IL-21 levels than healthy controls and patients with
mild AD (EASI < 10) (Fig. 1b), and serum IL-21 levels were signiﬁ-
cantly associated with the EASI score (Fig. 2). The serum levels of
IL-21 were also correlated with the erythema score and the edema/
papules score among six types of eruptions, erythema, edema/
papules, oozing/crusting, excoriation, licheniﬁcation, and xerosis
(Fig. 3).
In our study, serum IL-21 levels were signiﬁcantly elevated in
patients with severe AD, and they were signiﬁcantly correlated
with the disease severity of AD. These results suggest that IL-21
may contribute to the aggravation of AD lesions. It has been re-
ported that IL-21 and IL-21R expression were markedly upregu-
lated bymechanical injuries induced by subjecting tomouse skin to
tape stripping, and such injuries mimic AD lesions.12 In addition, as are elevated in atopic dermatitis patients with acute skin lesions,
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Fig. 2. Correlation between the serum IL-21 level and disease severity in AD patients
The correlation between the serum IL-21 level and disease severity (according to the
EASI score) was evaluated using Spearman's rank correlation analysis (n ¼ 79).
Fig. 1. Serum IL-21 levels of AD patients and healthy control. The serum IL-21 levels of AD patients (n ¼ 79) and healthy controls (n ¼ 17) were quantiﬁed (a). ManneWhitney's U
test was used to assess the signiﬁcance of differences. The serum IL-21 levels of AD patients were compared among 3 disease severity groups, the mild (score: <10) (n ¼ 21),
moderate (score: 10e20) (n ¼ 20), severe (score: >20) (n ¼ 38) groups (b). The Steel test and the SteeleDwass test were used to assess the signiﬁcance of differences. The data are
expressed as mean ± SD values. *P < 0.05.
H. Mizutani et al. / Allergology International xxx (2016) 1e5 3lack of IL-21R was shown to inhibit the trafﬁcking of skin dendritic
cells to draining lymph nodes and Th2-driven allergic skin
inﬂammation induced by epicutaneous sensitization with
experimental antigen chicken ovalbumin after tape stripping.12
Furthermore, IL-21 deﬁciency suppresses the development of
pathogen-induced Th2 responses and Th2 cytokine-dependent
ﬁbrosis.17e19 In our study, serum levels of IL-21 were also corre-
lated with the erythema score and the edema/papules score.Please cite this article in press as: Mizutani H, et al., Serum IL-21 level
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phase of AD.20 Our data are consistent with previous ﬁndings that
IL-21 and IL-21R expressions are upregulated in acute skin lesions
of AD.12 On the other hand, serum IL-21 was low or not detected in
AD patients with low degree of acute lesions although their skin
severity was severe. Taken together, these ﬁndings suggest that it
can be stated that IL-21 may increase Th2-type allergic inﬂamma-
tion, leading to the development of acute lesions in AD.
The administration of IL-21 suppresses Th2-driven allergic
inﬂammation, including IgE production, while IL-21 deﬁciency in-
hibits the development of Th2-dependent responses. The admin-
istration of IL-21 might downregulate IgE production by inhibiting
C 3germline transcription and restricting the switching of IgG1þ B
cells to IgEþ B cells in mice.21,22 Negative correlations between the
serum levels of IL-21 and IgE have been observed in a mouse model
of allergic rhinitis and in human atopic asthma.23 Moreover, the
administration of IL-21 suppressed mast cell granulation in murine
skin affected by immediate-type hypersensitivity.24 Therefore,
IL-21 is considered to be a pleiotropic cytokine that has different
effects on immune reactions depending on experimental condi-
tions. Contrary to our ﬁndings, a previous study showed that chil-
dren with AD had lower serum IL-21 levels than the controls.25
Therefore, the effect of IL-21 on immune reactions in adult AD
patients might differ from that seen in atopic children, possibly
because of differences between the pathogenic mechanisms of AD
between adults and children.
IL-21 is produced by various subsets of activated CD4þ T cells.
Several studies have suggested that Th2 and T follicular helper cells
function in close co-operation during Th2-driven immune re-
sponses.19,26 Interestingly, common allergens, house dust mites
were shown to induce IL-21 expression by T follicular helper cells in
the lymph nodes of allergic model mice.19 In AD, the production of
thymic stromal lymphopoietin (TSLP) is known to increase in
injured skin and to induce Th2-type allergic inﬂammation.15,27 Its are elevated in atopic dermatitis patients with acute skin lesions,
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Fig. 3. Correlations between the serum IL-21 level and eruption type in AD patients The correlations between the serum IL-21 level and disease severity (the scores for erythema,
edema/papules, oozing/crusting, excoriation, licheniﬁcation, and xerosis) were evaluated using Spearman's rank correlation analysis.
Table 1
Correlation between serum interleukin 21 levels and laboratory markers.
r P
Serum IgE levels (n ¼ 72) 0.036 0.763
Peripheral eosinophil count (n ¼ 71) 0.030 0.804
Serum LDH (n ¼ 73) 0.076 0.517
Serum TARC (n ¼ 75) 0.0080 0.945
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Allergology International (2016), http://dx.doi.org/10.1016/j.alit.2016.10.0has been reported that TSLP increases IL-21 production in mast
cells.12 Moreover, exogenous stimuli, such as ultraviolet B, can
induce IL-21 production in keratinocytes.28 Furthermore, it has
been reported that serum IL-21 levels increase in patients with
other inﬂammatory skin diseases such as psoriasis.29 Taken
together, these ﬁndings suggest that various factors, including
exogenous allergens and mechanical injury, can induce IL-21s are elevated in atopic dermatitis patients with acute skin lesions,
10
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conditions.
In conclusion, this study showed that AD patients, especially
those with acute lesions, exhibited elevated serum IL-21 levels.
Therefore, IL-21 might be associated with the acute aggravation of
AD. This cytokine could be an appropriate therapeutic target in
adult patients with severe AD symptoms.
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